Semaglutide (injectable) vs Orforglipron
Key distinction is injectable peptide GLP-1 versus daily oral non-peptide GLP-1; compare evidence maturity, formulation, label, efficacy and tolerability without cross-trial winner claims.
| Attribute | Semaglutide (injectable) | Orforglipron |
|---|---|---|
| Human evidence | Extensive Phase III evidence supports weight loss with regulated semaglutide. SELECT demonstrated cardiovascular benefit in a defined population, and STEP 9 showed improved knee-OA pain/function in adults with obesity. | Large Phase III trials demonstrate clinically meaningful weight loss and glycaemic efficacy with oral orforglipron. |
| Research focus | Obesity, weight management, cardiovascular outcomes, heart failure, osteoarthritis, type 2 diabetes | Obesity, weight management, type 2 diabetes, cardiometabolic risk |
| Regulatory status | Wegovy (semaglutide) is authorised in the EU for weight management in defined adults and adolescents; authorisation and dosing are product-, route-, indication- and jurisdiction-specific. | FDA approved Foundayo (orforglipron) on 1 April 2026 for chronic weight management in adults with obesity, or overweight with at least one weight-related comorbidity; approval is product/indication/jurisdiction specific. |
| Route / formulation | Evidence for licensed pre-filled injection pens cannot establish identity, concentration, sterility or equivalence of unverified semaglutide vials or non-authorised products. | Current labelled Foundayo tablet strengths/dose escalation must be kept separate from numeric doses used in earlier Phase III trial publications. |
Why these are compared
These compounds appear in the weight & body composition / route evidence landscape, but they are not interchangeable. Semaglutide (injectable) is long-acting glp-1 receptor agonist peptide analogue studied in obesity, weight management, cardiovascular outcomes, heart failure, osteoarthritis, type 2 diabetes; Orforglipron is oral non-peptide small-molecule glp-1 receptor agonist studied in obesity, weight management, type 2 diabetes, cardiometabolic risk. The purpose of this page is to compare the evidence base, not to recommend one compound over another.
Evidence maturity
Semaglutide (injectable): Approved medicine — extensive multi-outcome evidence, formulation/indication specific.
Orforglipron: FDA-approved U.S. weight-management medicine; strong Phase III evidence.
The table above gives the fuller human-evidence, regulatory and formulation context. Open the individual profiles for study-level records, limitations and source provenance.
What this comparison can and cannot establish
No single definitive all-population head-to-head outcome basis in current dataset. Cross-study comparisons can be distorted by differences in population, route, formulation, dose, duration and endpoint. WhichPeps therefore does not turn indirect comparisons into a treatment recommendation or name a winner. A well-designed head-to-head human trial using comparable populations and clinically relevant outcomes would reduce uncertainty.